By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Takeda Pharmaceutical Co. et al. v. Accord Healthcare, Inc.
1:11-cv-06360; filed September 12, 2011 in the Southern District of New York
• Plaintiffs: Takeda Pharmaceutical Co.; Takeda Pharmaceuticals North America, Inc.
• Defendant: Accord Healthcare, Inc.
Infringement of U.S. Patent Nos. 5,965,584 ("Pharmaceutical Composition," issued October 12, 1999), 6,329,404 (same title, issued December 11, 2001), 6,166,043 (same title, issued December 26, 2000), 6,172,090 (same title, issued January 9, 2001), 6,211,205 (same title, issued April 3, 2001), 6,271,243 (same title, issued August 7, 2001), and 6,303,640 (same title, issued October 16, 2001) following a Paragraph IV certification as part of Accord's filing of an ANDA to manufacture a generic version of Takeda's Actos® (pioglitazone hydrochloride, used to treat type II diabetes). View the complaint here.
Novartis AG et al. v. Accord Healthcare, Inc. USA et al.
1:11-cv-01631; filed September 9, 2011 in the District Court of the District of Columbia
• Plaintiffs: Novartis AG; Novartis Pharmaceuticals Corp.
• Defendants: Accord Healthcare, Inc. USA; Intas Pharmaceutical Ltd.
Infringement of U.S. Patent Nos. 6,025,391 ("Enteric-Coated Pharmaceutical Compositions of Mycophenolate," issued February 15, 2000), 6,172,107 ("Entric-Coated Pharmaceutical Compositions," issued January 9, 2001), and 6,306,900 (same title, issued October 23, 2001) following a Paragraph IV certification as part of Accord's filing of an ANDA to manufacture a generic version of Novartis' Myfortic® (mycophenolate sodium, used for the prophylaxis or prevention of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids). View the complaint here.
Abbott Laboratories et al. v. Hospira Inc.
1:11-cv-00795; filed September 9, 2011 in the District Court of Delaware
• Plaintiffs: Abbott Laboratories; Wisconsin Alumni Research Foundation
• Defendant: Hospira Inc.
Infringement of U.S. Patent No. 5,587,497 ("19-nor-Vitamin D Compounds," issued December 24, 1996) following a Paragraph IV certification as part of Hospira's filing of an NDA (under § 505(b)(2) of the Food, Drug and Cosmetic Act) to manufacture a generic version of Abbott's Zemplar® (paricalcitol, used to treat secondary hyperparathyroidism in patients with kidney failure). View the complaint here.
Flamel Technologies S.A. v. Anchen Pharmaceuticals, Inc.
1:11-cv-02570; filed September 9, 2011 in the District Court of Maryland
Infringement of U.S. Patent No. 6,022,562 ("Medicinal and/or Nutritional Microcapsules for Oral Administration," issued February 8, 2000) following a Paragraph IV certification as part of Anchen's filing of an ANDA to manufacture a generic version of GSK's Coreg® CR (carvedilol, used to treat congestive heart failure). View the complaint here.
GlaxoSmithKline LLC v. Mylan Inc. et al.
1:11-cv-00789; filed September 8, 2011 in the District Court of Delaware
• Plaintiff: GlaxoSmithKline LLC
• Defendants: Mylan Inc.; Mylan Pharmaceuticals Inc.; Impax Laboratories Inc.
Infringement of U.S. Patent Nos. 5,565,467 ("Androstenone Derivative," issued October 15, 1996), 5,846,976 (same title, issued December 8, 1998), and 5,998,427 ("Androstenones," issued December 7, 1999) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of GSK's Avodart® (dutasteride, used to treat symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate) and GSK's Jalyn® (dutasteride and tamsulosin hydrochloride, used to treat symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate). View the complaint here.
Cephalon Inc. et al. v. Sandoz Inc.
1:11-cv-00782; filed September 6, 2011 in the District Court of Delaware
• Plaintiffs: Cephalon Inc.; Cephalon France
• Defendant: Sandoz Inc.
Infringement of U.S. Patent No. 7,132,570 ("Method for the Production of Crystalline Forms of Optical Enantiomers of Modafinil," issued November 7, 2006) following a Paragraph IV certification as part of Sandoz's amendment of its ANDA to manufacture a generic version of Cephalon's Nuvigil® (armodafinil, used to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome, narcolepsy, and shift work sleep disorder). View the complaint here.
Comments